Literature DB >> 23571855

Generation and characterization of virus-free reprogrammed melanoma cells by the piggyBac transposon.

Juan Yin1, Yongna Fan, Dingxin Qin, Xiaocui Xiaocui Bian, Xiaobao Bi.   

Abstract

PURPOSE: Reprogramming of cancer cells to stem cell-like state provides a promising tool for the study of cancer pathogenesis and drug screening. However, most instances of direct reprogramming have been achieved by forced co-expression of defined transcription factors using viral vectors. Retroviral transduction as well as the ectopic expression of reprogramming factors may alter the differentiation potential of reprogrammed cancer cells or induce malignant transformation. Therefore, generation of reprogrammed cancer cells via virus-free reprogramming strategy needs to be studied.
METHODS: Melanoma cells were reprogrammed by co-expression of doxycycline-inducible Oct4, Sox2, Klf4, and c-Myc using the piggyBac (PB) transposon system. The expression level of genes was analyzed through RT-PCR, Western blot, and immunofluorescence. Epigenetic modification of genes was detected by bisulfite genomic sequencing. Post reprogrammed melanoma cells were generated through differentiation of reprogrammed melanoma cells. Sensitivity to chemotherapeutic agents and metastasis potential were investigated in post reprogrammed melanoma cells.
RESULTS: The virus-free reprogrammed melanoma cells were positive for stem cell markers including Oct4, Nanog, and SSEA-1, and the promoters of Nanog and Oct4 were demethylated. Moreover, reprogrammed melanoma cells gained differentiation potential and higher sensitivity to differentiation-inducing drugs. Post reprogrammed melanoma cells showed lower proliferation rate and metastatic potential compared with the parental cells.
CONCLUSIONS: Our results indicate that PB transposon-based method is applicable to generate virus-free reprogrammed melanoma cells. These cells can differentiate into other lineages with loss of malignant phenotypes, which may provide a more suitable source for molding of cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571855     DOI: 10.1007/s00432-013-1431-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  32 in total

Review 1.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

2.  Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution.

Authors:  Nimet Maherali; Rupa Sridharan; Wei Xie; Jochen Utikal; Sarah Eminli; Katrin Arnold; Matthias Stadtfeld; Robin Yachechko; Jason Tchieu; Rudolf Jaenisch; Kathrin Plath; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

3.  Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.

Authors:  Ken-ichi Nagai; Hideshi Ishii; Norikatsu Miyoshi; Hiromitsu Hoshino; Toshiyuki Saito; Tetsuya Sato; Yoshito Tomimaru; Shogo Kobayashi; Hiroaki Nagano; Mitsugu Sekimoto; Yuichiro Doki; Masaki Mori
Journal:  Biochem Biophys Res Commun       Date:  2010-04-07       Impact factor: 3.575

Review 4.  Induced pluripotent cancer cells: progress and application.

Authors:  Chun Sun; Yin Kun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-11-26       Impact factor: 4.553

5.  Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector.

Authors:  Cesar A Sommer; Andreia Gianotti Sommer; Tyler A Longmire; Constantina Christodoulou; Dolly D Thomas; Monica Gostissa; Fred W Alt; George J Murphy; Darrell N Kotton; Gustavo Mostoslavsky
Journal:  Stem Cells       Date:  2010-01       Impact factor: 6.277

6.  Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors.

Authors:  M Nishi; Y Sakai; H Akutsu; Y Nagashima; G Quinn; S Masui; H Kimura; K Perrem; A Umezawa; N Yamamoto; S W Lee; A Ryo
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 7.  Plasticity of the cancer cell: implications for epigenetic control of melanoma and other malignancies.

Authors:  George Lipkin
Journal:  J Invest Dermatol       Date:  2008-04-10       Impact factor: 8.551

8.  Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.

Authors:  X Zhang; F D Cruz; M Terry; F Remotti; I Matushansky
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

Review 9.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

10.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.

Authors:  Knut Woltjen; Iacovos P Michael; Paria Mohseni; Ridham Desai; Maria Mileikovsky; Riikka Hämäläinen; Rebecca Cowling; Wei Wang; Pentao Liu; Marina Gertsenstein; Keisuke Kaji; Hoon-Ki Sung; Andras Nagy
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  3 in total

Review 1.  Application of induced pluripotency in cancer studies.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Maciej Wiznerowicz
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-24

Review 2.  Chinese Herbs Interfering with Cancer Reprogramming Metabolism.

Authors:  Zhangfeng Zhong; William W Qiang; Wen Tan; Haotian Zhang; Shengpeng Wang; Chunming Wang; Wenan Qiang; Yitao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-05       Impact factor: 2.629

3.  Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells.

Authors:  S M Rafiqul Islam; Yusuke Suenaga; Atsushi Takatori; Yasuji Ueda; Yoshiki Kaneko; Hidetada Kawana; Makiko Itami; Miki Ohira; Sana Yokoi; Akira Nakagawara
Journal:  Cancer Sci       Date:  2015-08-18       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.